Astellas Gets $90M From Lupin In Myrbetriq Patent Deal
Generic-drug maker Lupin Pharmaceuticals has inked a deal to pay $90 million to settle claims that it infringed patents held by rival Astellas Pharma Inc. covering name-brand bladder drug Myrbetriq....To view the full article, register now.
Already a subscriber? Click here to view full article